A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease

Sponsor
Shandong Suncadia Medicine Co., Ltd.
Study ID
NCT07419828
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • HRS-1780 tablets — DRUG
    Oral tablets
  • Placebo — DRUG
    Oral tablets

Study Details

The study is a Phase III clinical trial to evaluate the superiority of HRS-1780 tablets compared with placebo in delaying renal function decline in participants with chronic kidney disease (CKD) on the basis of standard treatment.

Key Dates

First listed
Feb 19, 2026
Start date
Mar 13, 2026
Status verified
Nov 2025
Primary completion
Apr 30, 2030
Completion
May 31, 2030

Study Design

Enrollment
5,386 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: HRS-1780 tablets
  • Placebo Comparator: Placebo

Primary Outcome Measure

Time to the first appearance of the composite endpoint: [ Time Frame: month 60 ]

Central Contacts

Find similar trials

Nationwide
Chronic kidney disease trialsNephrology trialsKidney disease trials

Related Studies